You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on BRAF biomarkers.
Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health.
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
The researchers aim to offer the half-hour diagnostic assay for use during neurosurgery to help clinicians pursue the best treatment for patients with gliomas.
The so-called universal CDx approved by the FDA can gauge alterations across multiple genes associated with response to three lung cancer treatments.
Last week's buys of two oncology labs will allow Quest to provide new cancer diagnostic technologies to communities lacking major cancer research centers, it said.
Researchers said that laboratories participating in BRAF proficiency testing include most of the required reporting elements "to unambiguously convey molecular results."
The combination of the new test with Biocartis' existing KRAS assay offers customers a complete solution for testing metastatic colorectal cancers as reccomended by professional guidelines.
The Taiwanese research team that developed the method showed in a new study that it could better detect BRAF mutations than conventional PCR plus Sanger sequencing.